Altered expression of the plasminogen activation pathway in peripheral blood mononuclear cells in multiple sclerosis: Possible pathomechanism of matrix metalloproteinase activation

Multiple Sclerosis Journal

Volumn 19, Issue 10, 2013, Pages 1268-1274

  Cox, Mathew B ^a,d   Bowden, Nikola A ^a,d   Scott, Rodney J ^a,b,d   Lechner Scott, Jeannette ^a,b,c,d  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

^c Hunter New England Local Health Network   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

disease modifying treatment; genetics; interferon beta; Multiple sclerosis

Indexed keywords

BETA1A INTERFERON; FC RECEPTOR; GELATINASE B; HLA C ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; INTERFERON BETA SERINE; INTERLEUKIN 8; OVALBUMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMINOGEN ACTIVATION; SIGNAL TRANSDUCTION;

DISEASE MODIFYING TREATMENT; GENETICS; INTERFERON-BETA; MULTIPLE SCLEROSIS;

ADULT; ENZYME ACTIVATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PLASMINOGEN; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84883402800     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513475493     Document Type: Article

References (32)

1. Larochelle C, Alvarez JI, Prat A. How do immune cells overcome the blood-brain barrier in multiple sclerosis?. FEBS Lett. 2011 ; 585: 3770-3780
2. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: A retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 ; 8: 254-260
3. Sanford M, Lyseng-Williamson KA. Subcutaneous recombinant interferon-beta-1a (Rebif(R)): A review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2011 ; 71: 1865-1891
4. Lim SY, Constantinescu CS. Current and future disease-modifying therapies in multiple sclerosis. Int J Clin Pract. 2010 ; 64: 637-650
5. Carter NJ, Keating GM. Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs. 2010 ; 70: 1545-1577
6. Sawcer S, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
7. Kemppinen A, Sawcer S, Compston A. Genome-wide association studies in multiple sclerosis: Lessons and future prospects. Brief Funct Genomics. 2011 ; 10: 61-70
8. Booth DR, Arthur AT, Teutsch SM, et al. Gene expression and genotyping studies implicate the interleukin 7 receptor in the pathogenesis of primary progressive multiple sclerosis. J Mol Med. 2005 ; 83: 822-830
9. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007 ; 357: 851-862
10. Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor a chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet. 2007 ; 39: 1083-1091
11. Lundmark F, Duvefelt K, Iacobaeus E, et al. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet. 2007 ; 39: 1108-1113
12. Kemppinen AK, Kaprio J, Palotie A, et al. Systematic review of genome-wide expression studies in multiple sclerosis. BMJ Open. 2011 ; 1: e000053
13. Croze E. Differential gene expression and translational approaches to identify biomarkers of interferon beta activity in multiple sclerosis. J Interferon Cytokine Res. 2010 ; 30: 743-749
14. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol. 2005 ; 58: 840-846
15. Thomas PD, Kejariwal A, Guo N, et al. Applications for protein sequence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucl Acids Res. 2006 ; 34: W645 - W650
16. Thomas PD, Kejariwal A, Campbell MJ, et al. PANTHER: A browsable database of gene products organized by biological function, using curated protein family and subfamily classification. Nucleic Acids Res. 2003 ; 31: 334-341
17. Chevyreva I, Faull RL, Green CR, et al. Assessing RNA quality in postmortem human brain tissue. Exp Mol Pathol. 2008 ; 84: 71-77
18. Dutta R, Trapp BD. Gene expression profiling in multiple sclerosis brain. Neurobiol Dis. 2012 ; 45: 108-114
19. Caillier SJ, Briggs F, Cree BAC, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol. 2008 ; 181: 5473-5480
20. De Jager PL, Jia X, Wang J, et al. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009 ; 41: 776-782
21. Chandler S, Miller KM, Clements JM, et al. Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview. J Neuroimmunol. 1997 ; 72: 155-161
22. Zhang H, Adwanikar H, Werb Z, et al. Matrix metalloproteinases and neurotrauma: evolving roles in injury and reparative processes. Neuroscientist. 2010 ; 16: 156-170
23. Mandel M, Gurevich M, Pauzner R, et al. Autoimmunity gene expression portrait: Specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol. 2004 ; 138: 164-170
24. Gveric D, Hanemaaijer R, Newcombe J, et al. Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain. 2001 ; 124: 1978-1988
25. Galboiz Y, Shapiro S, Lahat N, et al. Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol. 2001 ; 50: 443-451
26. Stuve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996 ; 40: 853-863
27. Dressel A, Mirowska-Guzel D, Gerlach C, et al. Migration of T-cell subsets in multiple sclerosis and the effect of interferon-beta1a. Acta Neurol Scand. 2007 ; 116: 164-168
28. Yen JH, Kong W, Ganea D. IFN-beta inhibits dendritic cell migration through STAT-1-mediated transcriptional suppression of CCR7 and matrix metalloproteinase 9. J Immunol. 2010 ; 184: 3478-3486
29. Mittelstadt ML, Patel RC. AP-1 Mediated transcriptional repression of matrix metalloproteinase-9 by recruitment of histone deacetylase 1 in response to interferon beta. PLoS One. 2012 ; 7: e42152
30. Comabella M, Rio J, Espejo C, et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol. 2009 ; 130: 145-150
31. Avolio C, Ruggieri M, Giuliani F, et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol. 2003 ; 136: 46-53
32. Ünsal Y, KIvIlcIm G, Ayşegül A, et al. Matrix metalloproteinase-7 and matrix metalloproteinase-9 in pediatric multiple sclerosis. Pediatr Neurol. 2012 ; 47: 171-176